Jorge Plutzky, M.D.,
Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors
09 avr. 2015 08h45 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Reaches Agreement With Sarissa Capital
30 mars 2015 08h30 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 30, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
10 mars 2015 16h25 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Observes Rare Disease Day
28 févr. 2015 07h15 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
26 févr. 2015 16h10 HE | Aegerion Pharmaceuticals, Inc.
- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
25 févr. 2015 16h10 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2014 Financial Results on Thursday, February 26
12 févr. 2015 07h55 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
10 févr. 2015 16h45 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference
05 févr. 2015 16h10 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuti
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
13 janv. 2015 20h30 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...